NCT01731002已完成2 期
A Phase 2, Double-masked, Randomized, Multi-center, Active-controlled, Dose-response Parallel-group Study Comparing the Safety and Ocular Hypotensive Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure
Aerie Pharmaceuticals22 个研究点 分布在 1 个国家目标入组 224 人开始时间: 2012年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 224
- 试验地点
- 22
- 主要终点
- Intraocular Pressure (IOP)
研究概览
简要总结
Double-masked, randomized, multi-center, dose-response, active-controlled parallel-comparison of AR-13324 to latanoprost
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years of age or greater.
- •Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT).
- •Unmedicated (post-washout) Intraocular Pressure (IOP) ≥ 24 mm Hg at 2 eligibility visits (08:00 hr), 2-7 days a part, and ≥ 22 mm Hg at 10:00 and 16:00 hrs at the second qualification visit. If only one eye meets the IOP criteria it must be the same eye that met the criteria at all the qualification timepoints.
- •Corrected visual acuity in each eye +1.0 logMAR or better by ETDRS in each eye (equivalent to 20/200).
- •Able and willing to give signed informed consent and follow study instructions.
排除标准
- •Glaucoma: pseudoexfoliation or pigment dispersion component, history of angle closure or narrow angles. Note: Previous laser peripheral iridotomy is NOT acceptable.
- •IOP > 36 mm Hg.
- •Known hypersensitivity to any component of the formulation (benzalkonium chloride, etc.), or to topical anesthetics.
- •Previous glaucoma intraocular surgery or glaucoma laser procedures in study eye(s, e.g., laser trabeculoplasty).
- •Refractive surgery in study eye(s) (e.g., radial keratotomy, photorefractive keratectomy (PRK), laser eye surgery (LASIK), etc.).
- •Ocular trauma within the past six months, or ocular surgery or laser treatment within the past three months prior to screening.
- •Evidence of ocular infection, inflammation, clinically significant blepharitis or conjunctivitis at screening (Visit 0), or a history of herpes simplex keratitis
- •Ocular medication of any kind within 30 days of Visit 0, with the exception of a) ocular hypotensive medications (which must be washed out according to the provided schedule), b) lid scrubs (which may be used prior to, but not after Visit 0) or c) lubricating drops for dry eye (which may be used throughout the study).
- •Clinically significant ocular disease (e.g. uveitis, severe keratoconjunctivitis sicca) which might interfere with the study, including glaucomatous damage so severe that washout of ocular hypotensive medications for one month is not judged safe (i.e., cup-disc ratio > 0.8).
- •Central corneal thickness greater than 600 µm.
- •Any abnormality preventing reliable applanation tonometry of either eye.
- •Clinically significant abnormalities (as determined by the treating physician) in laboratory tests at screening.
- •Known hypersensitivity or contraindication to latanoprost.
- •Clinically significant systemic disease (e.g., myasthenia gravis, hepatic, renal, endocrine or cardiovascular disorders) which might interfere with the study.
- •Participation in any investigational study within 30 days prior to screening.
- •Changes of systemic medication that could have a substantial effect on IOP within 30 days prior to screening, or anticipated during the study.
- •Due to the current status of the preclinical safety program, women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control. An adult woman is considered to be of childbearing potential unless she is one year post-menopausal or three months post-surgical sterilization. All females of childbearing potential must have a negative urine pregnancy test result at the screening examination and must not intend to become pregnant during the study.
研究组 & 干预措施
AR-13324 Ophthalmic Solution 0.01%
Experimental
1 drop to study eye once daily
干预措施: AR-13324 Ophthalmic Solution 0.01% (Drug)
AR-13324 Ophthalmic Solution 0.02%
Experimental
1 drop to study eye once daily
干预措施: AR-13324 Ophthalmic Solution 0.02% (Drug)
Latanoprost Ophthalmic Solution 0.005%
Active Comparator
1 drop to study eye once daily
干预措施: Latanoprost ophthalmic solution 0.005% (Drug)
结局指标
主要结局
Intraocular Pressure (IOP)
时间窗: Study treatment was administered for 28 days
The primary efficacy endpoint was the mean IOP across subjects within treatment group on each day at each post-treatment timepoint. IOP was measured at 0800, 1000, and 1600 hours on days 0, 14, and 28. IOP was also measured at 0800 hours on Day 7 and follow-up days 29 and 30.
次要结局
- Extent of Exposure(28 Days)
研究者
研究点 (22)
Loading locations...
相似试验
Unknown
2 期
Study Evaluating the Efficacy and Safety of Miconazole Nitrate + Domiphen Bromide Vaginal Cream in the Treatment of Subjects With Acute Vulvovaginal CandidiasisAcute Vulvovaginal CandidiasisNCT04813822Aesculape CRO Belgium BV90
已完成
2 期
AR-12286 in Combination With LatanoprostGlaucomaOcular HypertensionNCT01302249Aerie Pharmaceuticals66
已完成
2 期
A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMDNeovascular Age-Related Macular DegenerationNCT03953079Graybug Vision56
已完成
2 期
A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye DiseaseDry Eye SyndromeNCT03404115Aldeyra Therapeutics, Inc.300
已完成
2 期
A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)Elevated Intraocular PressureNCT00902200Aerie Pharmaceuticals89